Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.

Enriqueta Felip,Filippo G de Braud,Michela Maur,Herbert H Loong,Alice Tsang Shaw,Johan F Vansteenkiste,Thomas John,Geoffrey Liu,Martijn P Lolkema,Giovanni Selvaggi,Vanessa Giannone, Pilar Cazorla,Jason Baum,O Alejandro Balbin,Luojun Victor Wang,Yvonne Y Lau,Jeffrey W Scott,Daniel Shao-Weng Tan

Journal of Thoracic Oncology（2020）

引用 53|浏览61

暂无评分

摘要

Ceritinib plus nivolumab has activity; ORR appears to correlate with PD-L1 at baseline. Toxicity, especially rash, is more common than with either single agent.

查看译文

关键词

Ceritinib,Nivolumab,ALK,PD-1,NSCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要